# HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates

- Link: https://www.thailand-business-news.com/pr-news/hkey-ai2vivo-1-0-hkeybio-accelerates-in-vivo-translation-for-ai-designed-candidates
- Published: 2026-07-30T20:06:00+07:00
- Author: PR Newswire

**HKEY-AI2Vivo™ 1.0** supports the move from computational hypotheses to in vivo
translational evidence in autoimmune and allergy research

BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ — HKeyBio has established **
HKEY-AI2Vivo™ 1.0**, its AI Candidate In Vivo Validation Acceleration Program. The
program supports AI drug-discovery teams in translating AI-generated targets, molecules
and mechanism hypotheses into in vivo pharmacology, mechanism, PK/PD, biomarker 
and pre-IND translational evidence in autoimmune and allergy disease models.

**HKEY-AI2Vivo™ 1.0 at a Glance**

**What it is:** HKEY-AI2Vivo™ 1.0 is HKeyBio’s in vivo validation service framework
for AI-generated drug candidates.

**Problem addressed:** It helps evaluate whether computational candidates can generate
interpretable pharmacology, mechanism and translational evidence in disease-relevant
in vivo models.

**Use cases:** The service is designed for AI drug discovery, AI antibody design,
AI protein design, overseas biotech programs and pre-IND strategy evaluation.

**HKeyBio capability link:** The framework draws on HKeyBio’s autoimmune and allergy
disease models, NHP translational research, pathology, immune assays, PK/PD and 
biomarker analysis.

**AI-generated candidates still need disease-relevant in vivo validation**

AI can accelerate target discovery, molecule generation and antibody design, but
disease-relevant pharmacology remains a critical bottleneck before candidates can
advance. For autoimmune and allergy programs, drug developers need interpretable
evidence across in vivo efficacy, pathology, immune phenotyping, PK/PD and biomarkers.

**HKEY-AI2Vivo™ 1.0 is structured around three validation needs**

**1. AI Candidate Quick Screen**

Designed for early-stage triage to help teams determine whether a candidate or mechanism
hypothesis warrants further in vivo evaluation.

**2. AI Autoimmune PoC Package**

Integrates efficacy evaluation, immune phenotyping, pathology, PK/PD and biomarker
analysis for candidate selection, financing, business development and pre-IND strategy
discussions.

**3. AI-Designed Biologics NHP Fast-PoM**

Supports small-scale NHP mechanism-of-action studies for AI-designed antibodies,
bispecifics, multispecifics and engineered proteins before IND-enabling development.

**HKeyBio provides a standardized path from intake to translational reporting**

The program may include an AI Candidate Validation Intake Form, feasibility assessment,
disease model recommendation, endpoint strategy, PK/PD planning, NHP necessity assessment
and English-language translational evidence reporting.

"AI is accelerating drug discovery, but disease-relevant in vivo evidence remains
a critical step before candidates can move forward," said the Head of Translational
Medicine at HKeyBio. "HKeyBio aims to be the validation partner that helps AI-native
biotech teams move from computational candidates to pharmacology, mechanism, PK/
PD, NHP and pre-IND evidence packages."

**About HKeyBio**

HKeyBio is a preclinical CRO specializing in autoimmune and allergic diseases, providing
full-process in vivo pharmacodynamic services. Positioned as an autoimmune disease
model expert, HKeyBio has established more than 50 NHP autoimmune and allergic disease
models, over 500 autoimmune and allergic disease animal models, and has accumulated
experience supporting more than 500 IND applications in autoimmune diseases.

**For more information, please contact:**

Website: [www.hkeybio.com](https://www.hkeybio.com/) 

Email: [tech@hkeybio.com](https://www.thailand-business-news.com/pr-news/tech@hkeybio.com)

Source note: Company information provided by HKeyBio, as of July 2026.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates ](http://www.prnasia.com/story/archive/5015699_CN15699_0?rand=184833)